Filtered By:
Specialty: Cardiology
Drug: Insulin

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 191 results found since Jan 2013.

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a 2-4x increased incidence of death from coronary artery disease. Patients with diabetes are considered for cardiovascular disease secondary prevention because their risk level is similar to that reported in patients without diabetes who have already suffered a myocardial infarction. More recently, with a better risk factors control, mainly in intensive LDL cholesterol target...
Source: Cardiovascular Diabetology - October 22, 2014 Category: Cardiology Authors: Francisco SaraivaAndrei Sposito Source Type: research

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus
Abstract Type 2 diabetes increases the risk of developing cardiovascular (CV) complications such as myocardial infarction, heart failure, stroke, peripheral vascular disease, and CV-associated mortality. Strict glycemic control in diabetics has shown improvement in microvascular complications related to diabetes but has been unable to demonstrate major effects on macrovascular complications including myocardial infarction and stroke. Conventional therapies for diabetes that include insulin, metformin, sulfonylureas (SU), and alpha-glucosidase inhibitors have limited and/or controversial data on CV safety based on...
Source: Current Cardiology Reports - October 10, 2014 Category: Cardiology Source Type: research

Metabolic syndrome in the prediction of cardiovascular events: the potential additive role of hsCRP and adiponectin
Conclusions MS is an important predictor of cardiovascular events and is most harmful in combination with high plasma hsCRP. The clustering of components is especially harmful.
Source: European Journal of Preventive Cardiology - September 16, 2014 Category: Cardiology Authors: Santaniemi, M., Ukkola, O., Malo, E., Bloigu, R., Kesaniemi, Y. A. Tags: Original scientific papers Source Type: research

Long-Term Outcome of PCI Versus CABG in Insulin and Non–Insulin-Treated Diabetic Patients Results From the FREEDOM Trial
BackgroundThe prospective, randomized FREEDOM (Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes) trial found coronary artery bypass graft surgery (CABG) was associated with better clinical outcomes than percutaneous coronary intervention (PCI) in patients with diabetes and multivessel disease, managed with or without insulin.ObjectivesIn this subgroup analysis of the FREEDOM trial, we examined the association of long-term clinical outcomes after revascularization in patients with insulin-treated diabetes mellitus (ITDM) compared with patients not treated with insulin.Method...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - September 15, 2014 Category: Cardiology Source Type: research

Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting
Conclusion Within a short period of 3–4 weeks, CR led to substantial improvements in key risk factors such as lipid profile, blood pressure, and physical fitness for all patients, even if CKD was present.
Source: European Journal of Preventive Cardiology - August 18, 2014 Category: Cardiology Authors: Voller, H., Gitt, A., Jannowitz, C., Karoff, M., Karmann, B., Pittrow, D., Reibis, R., Hildemann, S. Tags: Original scientific papers Source Type: research

Stroke Rounds: Link with Insulin Resistance May Vary by Race
(MedPage Today) -- Insulin resistance may be more closely tied to stroke risk among whites compared with blacks, an analysis of the REGARDS study showed.
Source: MedPage Today Cardiovascular - July 3, 2014 Category: Cardiology Source Type: news

Determinants of exercise peak arterial blood pressure, circulatory power, and exercise cardiac power in a population based sample of Finnish male and female aged 30 to 47 years: the Cardiovascular Risk in Young Finns Study
Conclusions: Subject demographics and lifestyle-related factors should be taken into account when exercise blood pressure response, CP and ECP are used to evaluate patients' cardiac function in CPET.
Source: BMC Cardiovascular Disorders - March 13, 2014 Category: Cardiology Authors: Janne HulkkonenHeikki AatolaKristiina PälveTerho LehtimäkiNina Hutri-KähönenJorma ViikariOlli RaitakariMika Kähönen Source Type: research

Rationale and design of the Steroids in Cardiac Surgery trial
Conclusions: SIRS will lead to a better understanding of the safety and efficacy of prophylactic steroids for cardiac surgery requiring CBP.
Source: American Heart Journal - March 3, 2014 Category: Cardiology Authors: Richard Whitlock, Kevin Teoh, Jessica Vincent, P.J. Devereaux, Andre Lamy, Domenico Paparella, Yunxia Zuo, Daniel I. Sessler, Pallav Shah, Juan-Carlos Villar, Ganesan Karthikeyan, Gerard Urrútia, Alvaro Alvezum, Xiaohe Zhang, Seyed Hesameddin Abbasi, Hon Tags: Trial Design Source Type: research

The relationship between insulin-sensitive obesity and cardiovascular diseases in a Chinese population: Results of the REACTION study
Conclusion: Both general and abdominal obesity were associated with elevated prevalent cardiovascular diseases and 10-year CHD risk, regardless of the presence or absence of insulin resistance.
Source: International Journal of Cardiology - February 6, 2014 Category: Cardiology Authors: Jieli Lu, Yufang Bi, Tiange Wang, Weiqing Wang, Yiming Mu, Jiajun Zhao, Chao Liu, Lulu Chen, Lixin Shi, Qiang Li, Qin Wan, Shengli Wu, Guijun Qin, Tao Yang, Li Yan, Yan Liu, Guixia Wang, Zuojie Luo, Xulei Tang, Gang Chen, Yanan Huo, Zhengnan Gao, Qing Su, Tags: Original Articles Source Type: research

Relationship of obesity and insulin resistance with the cerebrovascular reactivity: a case control study
Conclusions: We found a diminished vasomotor reactivity in individuals with obesity which was not explained by the presence of insulin resistance.
Source: Cardiovascular Diabetology - January 3, 2014 Category: Cardiology Authors: Marcela Rodríguez-FloresCarlos Cantú-BritoEduardo García-GarcíaClaudia Cano-Nigenda Source Type: research

Impact of Diabetes Mellitus on Early and Midterm Outcomes After Transcatheter Aortic Valve Implantation (from a Multicenter Registry)
In conclusion, DM does not significantly affect rates of complications in patients who underwent TAVI. Insulin-treated DM, but not orally treated DM, is independently associated with death and myocardial infarction at midterm follow-up and should be included into future TAVI-dedicated scores.
Source: The American Journal of Cardiology - November 13, 2013 Category: Cardiology Authors: Federico Conrotto, Fabrizio D'Ascenzo, Francesca Giordana, Stefano Salizzoni, Corrado Tamburino, Giuseppe Tarantini, Patrizia Presbitero, Marco Barbanti, Valeria Gasparetto, Marco Mennuni, Massimo Napodano, Marco L. Rossi, Michele La Torre, Gaetana Ferrar Tags: Valvular Heart Disease Source Type: research

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM), are at least 50 years old, have cardiovascular disease, and have an hemoglobin A1c value between 6.5% and 8.0%. Eligible participan...
Source: American Heart Journal - October 25, 2013 Category: Cardiology Authors: Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman Tags: Trial Design Source Type: research

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
Conclusion Severe hypoglycaemia is associated with an increased risk for CV outcomes in people at high CV risk and dysglycaemia. Although allocation to insulin glargine vs. standard care was associated with an increased risk of severe and non-severe hypoglycaemia, the relative risk of CV outcomes with hypoglycaemia was lower with insulin glargine-based glucose-lowering therapy than with the standard glycaemic control. Trial Registration (ORIGIN ClinicalTrials.gov number NCT00069784).
Source: European Heart Journal - October 21, 2013 Category: Cardiology Authors: The ORIGIN Trial Investigators, Mellbin, Ryden, Riddle, Probstfield, Rosenstock, Diaz, Yusuf, Gerstein Tags: Disease management Source Type: research

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions: LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 4, 2013 Category: Cardiology Authors: Steven P. Marso, Neil R. Poulter, Steven E. Nissen, Michael A. Nauck, Bernard Zinman, Gilbert H. Daniels, Stuart Pocock, William M. Steinberg, Richard M. Bergenstal, Johannes F.E. Mann, Lasse Steen Ravn, Kirstine Brown Frandsen, Alan C. Moses, John B. Bus Tags: Trial Design Source Type: research